SEVOMAR-800 TAB

Uses of SEVOMAR-800 TAB

SEVOMAR-800 TAB is primarily used to control serum phosphorus levels in patients with chronic kidney disease (CKD) who are on dialysis.

• Hyperphosphatemia in CKD on Dialysis

  SEVOMAR-800 TAB is indicated for the reduction of serum phosphorus in adult and pediatric patients (6 years and older) with chronic kidney disease (CKD) on dialysis. High phosphate levels can lead to secondary hyperparathyroidism, renal osteodystrophy, and increased cardiovascular risk. This medication helps maintain phosphate within the target range, improving patient quality of life and reducing long-term complications associated with elevated phosphorus.

• Hyperphosphatemia in CKD Not on Dialysis

  While primarily used in dialysis patients, SEVOMAR-800 TAB may also be prescribed off-label or in specific cases for managing hyperphosphatemia in adult CKD patients who are not yet on dialysis, under strict medical supervision. Controlling phosphate levels early can help slow the progression of mineral and bone disorders and mitigate cardiovascular risks before dialysis initiation becomes necessary. Always consult a nephrologist for appropriate management.

• Prevention of Vascular Calcification

  By effectively lowering serum phosphate levels, SEVOMAR-800 TAB indirectly contributes to the prevention or slowing of vascular calcification, a significant complication in CKD patients. Vascular calcification is a strong predictor of cardiovascular morbidity and mortality. Maintaining optimal phosphate balance with medications like Sevelamer is a key strategy in reducing this serious risk and improving overall prognosis for renal patients.

Side Effects of SEVOMAR-800 TAB

Like all medicines, SEVOMAR-800 TAB can cause side effects, although not everybody gets them. Most side effects are mild to moderate and related to the gastrointestinal system.

Less common or rare side effects may include more serious gastrointestinal issues or other systemic reactions. Seek immediate medical attention if you experience any severe symptoms.

If any of these side effects bother you or do not go away, please consult your doctor. Do not stop taking the medication without speaking to your healthcare provider first.

How to use SEVOMAR-800 TAB

• Adults:

  The recommended starting dose for adults is 800 mg to 1600 mg (1-2 tablets) three times a day with meals, based on serum phosphate levels. Dosage should be adjusted in increments of 800 mg per day every 2-4 weeks until the target serum phosphate level is achieved. The maximum daily dose can be up to 13 grams, but typically ranges from 6-9 grams per day. Tablets should be swallowed whole and not crushed, chewed, or broken.

• Children:

  For pediatric patients (6 years and older) with CKD on dialysis, the starting dose is based on body surface area (BSA) or weight, typically 400 mg to 800 mg three times a day with meals. Dosage adjustments should be made based on serum phosphate levels and tolerance, under the guidance of a pediatric nephrologist. Tablets should be administered with meals and swallowed whole.

• Elderly:

  No specific dose adjustment is required for elderly patients. The dosage should be individualized based on serum phosphate levels and tolerance, similar to adult patients. Close monitoring for potential side effects is advisable, although Sevelamer is generally well-tolerated in this population.

• Missed Dose:

  If you miss a dose of SEVOMAR-800 TAB, take it with your next meal. Do not take a double dose to make up for a missed one. Consistent dosing with meals is important for effective phosphate binding. If you frequently miss doses, discuss this with your doctor or pharmacist to find strategies to improve adherence.

How SEVOMAR-800 TAB works

Sevelamer, the active ingredient in SEVOMAR-800 TAB, is a non-absorbed, polymeric phosphate binder. When taken orally, it exchanges chloride ions for phosphate ions in the gastrointestinal lumen. This ionic exchange leads to the formation of an insoluble complex between sevelamer and phosphate, which is then excreted in the feces. By preventing the absorption of dietary phosphate, Sevelamer effectively lowers serum phosphate concentrations in patients with hyperphosphatemia. This mechanism is crucial for CKD patients, as their impaired kidneys are unable to excrete excess phosphate efficiently. The binding capacity of sevelamer is pH-dependent, with optimal binding occurring at the acidic pH found in the stomach and small intestine. Unlike calcium-based binders, sevelamer does not contribute to calcium load, reducing the risk of hypercalcemia, a common concern in CKD management. Its non-metallic nature also avoids the risks associated with aluminum accumulation.

Precautions

• Do not take SEVOMAR-800 TAB if you have hypophosphatemia (low blood phosphate levels) or bowel obstruction.
• Monitor serum calcium, phosphate, bicarbonate, and chloride levels regularly during treatment.
• Patients with dysphagia, swallowing disorders, severe gastrointestinal motility disorders, or major gastrointestinal surgery should use with caution.
• May decrease the absorption of certain fat-soluble vitamins (A, D, E, K) and folic acid. Supplementation may be required.
• Administer other oral medications at least one hour before or three hours after SEVOMAR-800 TAB to avoid potential binding and reduced absorption.
• Not studied in patients with acute peritonitis or severe active inflammatory bowel disease.

Safety Advice

Alcohol

CAUTION

There is no known direct interaction between alcohol and Sevelamer. However, excessive alcohol consumption can worsen overall health, especially in patients with chronic kidney disease. It's advisable to limit or avoid alcohol intake.

Pregnancy

CONSULT YOUR DOCTOR

SEVOMAR-800 TAB should be used during pregnancy only if clearly needed and the potential benefits outweigh the risks. Animal studies have shown no evidence of teratogenicity, but human data is limited. Always discuss with your doctor if you are pregnant or planning to conceive.

Breastfeeding

CONSULT YOUR DOCTOR

It is unknown whether Sevelamer is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SEVOMAR-800 TAB is administered to a nursing woman. Consult your doctor to weigh the potential risks and benefits.

Driving

SAFE

SEVOMAR-800 TAB is not known to impair the ability to drive or operate machinery. It does not typically cause drowsiness or dizziness. You can safely drive unless you experience any unusual side effects that affect your concentration.

Kidney

SAFE IF PRESCRIBED

SEVOMAR-800 TAB is specifically designed for patients with chronic kidney disease to manage hyperphosphatemia. It is safe and effective for kidney patients when used as prescribed by a nephrologist. Regular monitoring of phosphate levels is crucial.

Liver

CONSULT YOUR DOCTOR

Sevelamer is not absorbed systemically and is not metabolized by the liver, so liver impairment is not expected to affect its pharmacokinetics. However, patients with severe liver disease should consult their doctor before starting treatment, as their overall health status may require careful consideration.

Fact Box

Frequently asked questions by patients

Frequently Asked Questions

Additional Information